Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO

被引:119
作者
Euhus, DM
Smith, KC
Robinson, L
Stucky, A
Olopade, OI
Cummings, S
Garber, JE
Chittenden, A
Mills, GB
Rieger, P
Esserman, L
Crawford, B
Hughes, KS
Roche, CA
Ganz, PA
Seldon, J
Fabian, CJ
Klemp, J
Tomlinson, G
机构
[1] Univ Texas, SW Med Ctr, Div Surg Oncol, Dallas, TX 75390 USA
[2] Univ Chicago, Chicago, IL 60637 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Univ Calif San Francisco, Med Ctr, San Francisco, CA 94143 USA
[6] Massachusetts Gen Hosp, Boston, MA 02114 USA
[7] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA
[8] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
关键词
D O I
10.1093/jnci/94.11.844
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Because BRCA gene mutation testing is costly, occasionally uninformative, and frequently associated with ethical and legal issues, careful patient selection is required prior to testing. Estimation of BRCA gene mutation probability is an important component of pretest counseling, but the accuracy of these estimates is currently unknown. We measured the performance of eight cancer risk counselors and of a computer model, BRCAPRO, at identifying families likely to carry a BRCA gene mutation. Methods: Eight cancer risk counselors and the computer model BRCAPRO estimated BRCA gene mutation probabilities for 148 pedigrees selected from an initial sample of 272 pedigrees. The final sample was limited to pedigrees with a proband affected by breast or ovarian cancer and BRCA1 and BRCA2 gene sequencing results unequivocally reported as negative or positive for a deleterious mutation. Sensitivity, specificity, negative predictive value, positive predictive value, and areas under receiver operator characteristics (ROC) curves were calculated for each risk counselor and for BRCAPRO. All statistical tests were two sided. Results: Using a greater-than-10% BRCA gene mutation probability threshold, the median sensitivity for identifying mutation carriers was 94% (range = 81% to 98%) for the eight risk counselors and 92% (range = 91% to 92%) for BRCAPRO. Median specificity at this threshold was 16% (range = 6% to 34%) for the risk counselors and 32% (range = 30% to 34%) for BRCAPRO (P =.04). Median area under the ROC curves was 0.671 for the risk counselors (range = 0.620 to 0.717) and 0.712 (range = 0.706 to 0.720) for BRCAPRO (P =.04). There was a slight, but not statistically significant, improvement in all counselor performance measures when BRCAPRO-assigned gene mutation probability information was included with the pedigrees. Conclusions: Sensitivity for identifying BRCA gene mutation carriers is similar for experienced risk counselors and the computer model BRCAPRO. Because the computer model consistently demonstrated superior specificity, overall discrimination between BRCA gene mutation carriers and BRCA gene mutation noncarriers was slightly better for BRCAPRO.
引用
收藏
页码:844 / 851
页数:8
相关论文
共 30 条
  • [1] *AM SOC CLIN ONC, 1994, GEN TEST CANC SUSC I
  • [2] Antoniou AC, 2000, GENET EPIDEMIOL, V18, P173
  • [3] Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history
    Berry, DA
    Parmigiani, G
    Sanchez, J
    Schildkraut, J
    Winer, E
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (03) : 227 - 238
  • [4] BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer
    Couch, FJ
    DeShano, ML
    Blackwood, MA
    Calzone, K
    Stopfer, J
    Campeau, L
    Ganguly, A
    Rebbeck, T
    Weber, BL
    Jablon, L
    Cobleigh, MA
    Hoskins, K
    Garber, JE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (20) : 1409 - 1415
  • [5] COMPARING THE AREAS UNDER 2 OR MORE CORRELATED RECEIVER OPERATING CHARACTERISTIC CURVES - A NONPARAMETRIC APPROACH
    DELONG, ER
    DELONG, DM
    CLARKEPEARSON, DI
    [J]. BIOMETRICS, 1988, 44 (03) : 837 - 845
  • [6] Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer
    Dorum, A
    Heimdal, K
    Hovig, E
    Inganäs, M
    Moller, P
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 65 (03) : 671 - 679
  • [7] Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13
    Easton, DF
    Steele, L
    Fields, P
    Ormiston, W
    Averill, D
    Daly, PA
    McManus, R
    Neuhausen, SL
    Ford, D
    Wooster, R
    CannonAlbright, LA
    Stratton, MR
    Goldgar, DE
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 61 (01) : 120 - 128
  • [8] EASTON DF, 1995, AM J HUM GENET, V56, P265
  • [9] Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families
    Ford, D
    Easton, DF
    Stratton, M
    Narod, S
    Goldgar, D
    Devilee, P
    Bishop, DT
    Weber, B
    Lenoir, G
    Chang-Claude, J
    Sobol, H
    Teare, MD
    Struewing, J
    Arason, A
    Scherneck, S
    Peto, J
    Rebbeck, TR
    Tonin, P
    Neuhausen, S
    Barkardottir, R
    Eyfjord, J
    Lynch, H
    Ponder, BAJ
    Gayther, SA
    Birch, JM
    Lindblom, A
    Stoppa-Lyonnet, D
    Bignon, Y
    Borg, A
    Hamann, U
    Haites, N
    Scott, RJ
    Maugard, CM
    Vasen, H
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (03) : 676 - 689
  • [10] RISKS OF CANCER IN BRCA1-MUTATION CARRIERS
    FORD, D
    EASTON, DF
    BISHOP, DT
    NAROD, SA
    GOLDGAR, DE
    HAITES, N
    MILNER, B
    ALLAN, L
    PONDER, BAJ
    PETO, J
    SMITH, S
    STRATTON, M
    LENOIR, GM
    FEUNTEUN, J
    LYNCH, H
    ARASON, A
    BARKARDOTTIR, R
    EGILSSON, V
    BLACK, DM
    KELSELL, D
    SPURR, N
    DEVILEE, P
    CORNELISSE, CJ
    VARSEN, H
    BIRCH, JM
    SKOLNICK, M
    SANTIBANEZKOREF, MS
    TEARE, D
    STEEL, M
    PORTER, D
    COHEN, BB
    CAROTHERS, A
    SMYTH, E
    WEBER, B
    NEWBOLD, B
    BOEHNKE, M
    COLLINS, FS
    CANNONALBRIGHT, LA
    GOLDGAR, D
    [J]. LANCET, 1994, 343 (8899) : 692 - 695